Neurocrine Launches Phase 1 Trial of NBIP-2118 Weight-Loss Agonist Preserving Lean Mass
Neurocrine Biosciences has initiated a Phase 1 first-in-human trial of NBIP-2118, a once-weekly CRF 2 receptor agonist, to evaluate safety and tolerability in healthy-weight, overweight and obese adults. Preclinical models showed NBIP-2118 reduced fat while preserving or increasing lean mass, with initial human data expected in 2027.
1. Phase 1 Trial Initiation
Neurocrine Biosciences has commenced a Phase 1 first-in-human study evaluating single ascending doses of NBIP-2118 against placebo in healthy-weight, overweight and obese adults to assess safety and tolerability over once-weekly subcutaneous administration. Initial enrollment and dose escalation will inform dosing parameters and safety profile.
2. Mechanism and Preclinical Findings
NBIP-2118 is a corticotropin-releasing factor type 2 receptor peptide agonist designed to reduce fat mass while preserving or increasing lean mass, including skeletal muscle. Preclinical models demonstrated high selectivity and potency with weight loss primarily driven by fat reduction and muscle-sparing benefits.
3. Pipeline and Strategic Context
This program is part of Neurocrine’s integrated obesity strategy, which includes NBIP-1968, a GLP-1/GIP/glucagon triple agonist intended for combination use, and other conjugated incretin–CRF 2 agonist molecules. The company views NBIP-2118 as both a standalone and combination therapy, with initial human data expected in 2027.